oltipraz has been researched along with Fatty Liver in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, J; Wang, SY | 1 |
| Kim, W; Kim, YJ | 1 |
| Chang, MS; Cho, JY; Kim, BG; Kim, H; Kim, JH; Kim, SG; Kim, W; Kim, YJ; Lee, CK; Lee, J; Lee, JH; Lee, JS; Yeon, JE; Yi, S | 1 |
| Bae, EJ; Hwahng, SH; Ki, SH; Kim, HE; Kim, SG | 1 |
| Brooks, JS; Brooks, SC; Kim, SG; Lee, MG; Lee, WH | 1 |
| Eom, JS; Kim, SG; Kim, TH; Lee, CG; Lee, YS; Yang, YM | 1 |
1 review(s) available for oltipraz and Fatty Liver
| Article | Year |
|---|---|
Therapeutic potential of dithiolethiones for hepatic diseases.
Topics: Animals; CCAAT-Enhancer-Binding Protein-beta; Fatty Liver; Glutathione Transferase; Humans; Inactivation, Metabolic; Insulin Resistance; Liver; Liver Cirrhosis; Liver Diseases; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Protein Kinases; Pyrazines; Receptors, Aryl Hydrocarbon; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Thiones; Thiophenes; TOR Serine-Threonine Kinases | 2009 |
1 trial(s) available for oltipraz and Fatty Liver
| Article | Year |
|---|---|
Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
Topics: Adult; Animals; Double-Blind Method; Fatty Liver; Female; Humans; Liver X Receptors; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Mice; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes; Treatment Outcome; Ultrasonography | 2017 |
4 other study(ies) available for oltipraz and Fatty Liver
| Article | Year |
|---|---|
Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed.
Topics: Fatty Liver; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes | 2017 |
Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed-authors' reply.
Topics: Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes | 2017 |
Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.
Topics: Animals; Cyclic AMP-Dependent Protein Kinases; DNA-Binding Proteins; Fatty Liver; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Orphan Nuclear Receptors; Pyrazines; Receptors, Cytoplasmic and Nuclear; Ribosomal Protein S6 Kinases, 70-kDa; Sterol Regulatory Element Binding Protein 1; Thiones; Thiophenes; Transcriptional Activation | 2009 |
An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Antioxidants; Diet, High-Fat; Enzyme Activation; Fatty Liver; Hep G2 Cells; Humans; Lipid Metabolism; Lipogenesis; Liver; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Mitochondria; Orphan Nuclear Receptors; Oxidation-Reduction; Oxidative Stress; Pyrazines; Sterol Regulatory Element Binding Protein 1; Thiones; Thiophenes | 2013 |